TWI851536B - 治療克羅恩氏病和潰瘍性結腸炎之方法 - Google Patents

治療克羅恩氏病和潰瘍性結腸炎之方法 Download PDF

Info

Publication number
TWI851536B
TWI851536B TW107108166A TW107108166A TWI851536B TW I851536 B TWI851536 B TW I851536B TW 107108166 A TW107108166 A TW 107108166A TW 107108166 A TW107108166 A TW 107108166A TW I851536 B TWI851536 B TW I851536B
Authority
TW
Taiwan
Prior art keywords
patient
weeks
pharmaceutically acceptable
acceptable salt
solid form
Prior art date
Application number
TW107108166A
Other languages
English (en)
Chinese (zh)
Other versions
TW201840318A (zh
Inventor
魯派爾Ｂ 塔克
史提芬 強葛維西
廸 拉希爾達 安那 保拉 馬恰多
安Ｍ 羅賓森
愛立Ｌ 潘根
茉漢姆德 雅斯藍 茉漢姆德
安姆 奧特曼
瓊斯 傑佛瑞Ｖ 艾妮瓊薩
班 庫倫德
艾門Ｄ 艾利恩
湯瑪士Ｂ 柏恰爾得
菲德瑞克 萊斯 諾斯瓊
亞曼德Ｙ 席可
馬修Ｍ 穆罕
賈亞新 賈亞斯
派翠克Ｊ 瑪倫
彼得Ｔ 梅爾
Original Assignee
美商艾伯維有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61750557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI851536(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商艾伯維有限公司 filed Critical 美商艾伯維有限公司
Publication of TW201840318A publication Critical patent/TW201840318A/zh
Application granted granted Critical
Publication of TWI851536B publication Critical patent/TWI851536B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW107108166A 2017-03-09 2018-03-09 治療克羅恩氏病和潰瘍性結腸炎之方法 TWI851536B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762469337P 2017-03-09 2017-03-09
US62/469,337 2017-03-09
US201762470565P 2017-03-13 2017-03-13
US62/470,565 2017-03-13
US201762483289P 2017-04-07 2017-04-07
US62/483,289 2017-04-07
US201762593629P 2017-12-01 2017-12-01
US62/593,629 2017-12-01

Publications (2)

Publication Number Publication Date
TW201840318A TW201840318A (zh) 2018-11-16
TWI851536B true TWI851536B (zh) 2024-08-11

Family

ID=61750557

Family Applications (2)

Application Number Title Priority Date Filing Date
TW107108166A TWI851536B (zh) 2017-03-09 2018-03-09 治療克羅恩氏病和潰瘍性結腸炎之方法
TW113126496A TW202517269A (zh) 2017-03-09 2018-03-09 治療克羅恩氏病和潰瘍性結腸炎之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113126496A TW202517269A (zh) 2017-03-09 2018-03-09 治療克羅恩氏病和潰瘍性結腸炎之方法

Country Status (9)

Country Link
US (3) US20190046527A1 (enExample)
EP (2) EP4487908A3 (enExample)
JP (2) JP2020510016A (enExample)
CN (2) CN120661512A (enExample)
AU (2) AU2018230500B2 (enExample)
BR (1) BR112019018576A2 (enExample)
MX (2) MX2019010733A (enExample)
TW (2) TWI851536B (enExample)
WO (2) WO2018165581A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3251507A1 (en) 2015-10-16 2025-05-21 Abbvie Inc. Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2018165581A1 (en) * 2017-03-09 2018-09-13 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US20220002306A1 (en) * 2018-09-29 2022-01-06 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of upadacitinib and preparation method and use thereof
EP3891151A1 (en) * 2018-12-05 2021-10-13 LEK Pharmaceuticals d.d. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
CN111909160B (zh) * 2019-05-09 2024-05-28 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
CN110101669A (zh) * 2019-06-11 2019-08-09 南京新酶合医药科技有限公司 一种乌帕替尼颗粒的生产工艺
BR112022005765A2 (pt) 2019-09-30 2022-06-21 Abbvie Inc Tratamento contra afecções espondiloartríticas e psoriáticas com upadacitinib
KR20230038229A (ko) 2020-07-08 2023-03-17 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 우파다시티닙의 결정형, 이의 제조 방법 및 이의 용도
US20240316040A1 (en) * 2020-12-29 2024-09-26 Abbvie Inc. Extended release upadacitinib formulations
CN114380837B (zh) * 2021-12-27 2023-06-30 上海邈金医药科技有限公司 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
AU2023206381A1 (en) * 2022-01-13 2024-07-25 Abbvie Inc. Method of administering upadacitinib to avoid adverse drug interactions and effects
EP4465971A1 (en) * 2022-01-20 2024-11-27 Renata Phramaceutical (Ireland) Limited Sustained release pharmaceutical composition of upadacitinib
WO2024052820A1 (en) * 2022-09-09 2024-03-14 Intas Pharmaceuticals Ltd. Upadacitinib formulation
US20240242807A1 (en) * 2023-01-17 2024-07-18 Children's Hospital Medical Center Model-informed precision dosing systems for treatment of inflammatory bowel disease
WO2025149974A1 (en) * 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
CN120699157B (zh) * 2025-07-16 2025-12-16 安康市中心医院 一种治疗溃疡性结肠炎的恢复肠屏障功能抗体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
MXPA06013250A (es) 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
CN100381175C (zh) 2004-10-09 2008-04-16 山西中医学院 一种微乳制剂及其制备方法
CN101389630A (zh) 2005-12-29 2009-03-18 艾博特公司 蛋白激酶抑制剂
CA2665214A1 (en) 2006-10-06 2008-05-29 Abbott Laboratories Novel imidazothiazoles and imidazoxazoles
PT2152250T (pt) 2007-05-07 2019-12-12 Evonik Operations Gmbh Formas farmacêuticas sólidas que compreendem um revestimento entérico com libertação acelerada do fármaco
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
US20120276206A1 (en) 2008-03-28 2012-11-01 Boehringer Ingelheim International Gmbh Method for manufacturing acid pellets
KR20110017431A (ko) 2008-06-10 2011-02-21 아보트 러보러터리즈 신규한 트리사이클릭 화합물
CN101904814A (zh) 2009-06-04 2010-12-08 上海恒瑞医药有限公司 制备载药乳剂的方法
CA2769760A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
TWI500620B (zh) 2009-12-01 2015-09-21 Abbvie Inc 新穎三環化合物
FR2991171B1 (fr) 2012-06-01 2014-05-23 Galderma Res & Dev Procede de preparation d'une composition dermatologique comprenant des oleosomes
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
CA2926361A1 (en) * 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
US20170266289A1 (en) 2014-08-27 2017-09-21 Abbvie Inc. Topical formulation
JP6796083B2 (ja) 2015-06-09 2020-12-02 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ カプセル中の薬剤の噴霧乾燥ディスパーションからの迅速な溶解を達成するための製剤
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CA3251507A1 (en) 2015-10-16 2025-05-21 Abbvie Inc. Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP4190318A1 (en) * 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
WO2018165581A1 (en) 2017-03-09 2018-09-13 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis

Also Published As

Publication number Publication date
US20210361647A1 (en) 2021-11-25
CN110392572A (zh) 2019-10-29
JP2020510016A (ja) 2020-04-02
EP4487908A2 (en) 2025-01-08
US11607411B2 (en) 2023-03-21
US20190046527A1 (en) 2019-02-14
AU2024203642B2 (en) 2025-08-21
BR112019018576A2 (pt) 2020-04-14
CA3052873A1 (en) 2018-09-13
AU2018230500A1 (en) 2019-09-19
CN120661512A (zh) 2025-09-19
AU2018230500B2 (en) 2024-03-07
TW202517269A (zh) 2025-05-01
JP2024009963A (ja) 2024-01-23
TW201840318A (zh) 2018-11-16
MX2019010733A (es) 2019-11-01
EP4487908A3 (en) 2025-01-15
WO2018165581A1 (en) 2018-09-13
US20220233527A1 (en) 2022-07-28
MX2022015499A (es) 2023-01-24
EP3592353A1 (en) 2020-01-15
WO2022178492A1 (en) 2022-08-25
AU2024203642A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
TWI851536B (zh) 治療克羅恩氏病和潰瘍性結腸炎之方法
US20230058001A1 (en) PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11535626B2 (en) Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof
US20220273651A1 (en) Methods of treating crohn's disease and ulcerative colitis
WO2016100310A1 (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
CA3052873C (en) Use of upadacitinib to treat crohn's disease and ulcerative colitis
HK40123037A (en) Methods of treating crohn's disease and ulcerative colitis
BR122022024891B1 (pt) Composição farmacêutica oral de liberação prolongada uma vez ao dia compreendendo (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]pirazin-8-il)-n- (2,2,2-trifluoroetil)pirroli-dina-1-carboxamida
HK1263380B (en) PROCESS FOR THE PREPARATION OF IMIDAZO[1,2-α]PYRROLO[2,3-E]PYRAZINE COMPOUND
BR112018007677B1 (pt) Hemi-hidrato cristalino do composto (3s,4r)-3-etil-4-(3h-imidazo[1,2-a] pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil)pirroli-dina-1-carboxamida
BR122022024919B1 (pt) Hidrato de tartarato cristalino do composto (3s,4r)-3-etil4-(3h-imidazo [1,2-a]pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil)pirroli-dina-1-carboxamida